GlassScriptPhysician profile
Praveen Thangada
NPI 1023078250
$6,336.11
in general payments reported to CMS, 2019-2025
28 companies · $624 in 2025
The $624 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $369 · 2021: $1,004 · 2022: $2,811 · 2023: $754 · 2024: $603 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,016.44 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Acadia Pharmaceuticals INC | $544.05 | 2021-2024 | Nuplazid |
| Mdd US Operations, LLC | $432.42 | 2020-2025 | Gocovri |
| Pfizer INC. | $387.42 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $375.12 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Lilly USA, LLC | $229.79 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $177.26 | 2022 | |
| Biogen, INC. | $157.26 | 2020-2022 | |
| Amgen INC. | $112.79 | 2021-2023 | Aimovig |
| Merz Pharmaceuticals, LLC | $93.82 | 2024-2025 | Inbrija, Xeomin |
| Adamas Pharmaceuticals, INC. | $91.73 | 2020-2021 | |
| Eisai INC. | $84.49 | 2021-2023 | |
| Lundbeck LLC | $64.73 | 2020-2024 | Rexulti |
| Allergan, INC. | $61.72 | 2020 | |
| Kyowa Kirin, INC. | $57.63 | 2021-2024 | Nourianz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $51.85 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $50.32 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $45.69 | 2020 | |
| Sk Life Science, INC. | $44.80 | 2021-2022 | |
| Medtronic, INC. | $41.89 | 2021-2025 | Percept PC Brainsense |
| Averitas Pharma INC. | $41.39 | 2023-2025 | Qutenza |
| Corium, LLC | $35.90 | 2023 | Adlarity |
| Biocodex, INC. | $28.14 | 2023 | Diacomit |
| Amneal Pharmaceuticals LLC | $27.99 | 2019-2023 | Rytary |
| Ucb, INC. | $27.23 | 2019 | |
| Livanova USA, INC. | $27.15 | 2019 | |
| Axsome Therapeutics, INC. | $14.49 | 2025 | Symbravo |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praveen Thangada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.